- Price
- $42.32
- Day
- +1.27%
- Mkt Cap
- $4.62B
- 52W Range
- $12.88 – $49.20
- Volume
- 1.86M
- Beta
- 2.21
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to six newly hired non-executive employees consisting of options to purchase an aggregate of 115,600 common shares of the Company (the "Options") with effective grant dates of August 3, 2026.
Read full article
The average of price targets set by Wall Street analysts indicates a potential upside of 34.9% in Definium Therapeutics, Inc. (DFTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read full article
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a webcast at 4:30 p.m. EDT on Thursday, August 6, 2026 to report financial results for the second quarter ended June 30, 2026, and discuss recent business highlights. Listeners can register for the webcast via this link.
Read full article
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to two newly hired non-executive employees consisting of options to purchase an aggregate of 30,330 common shares of the Company (the "Options") with effective grant dates of July 20, 2026.
Read full article
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the launch of Wired for Worry, a new healthcare provider disease education initiative focused on generalized anxiety disorder (GAD). Wired for Worry is designed to meet a critical need to broaden understanding of GAD through.
Read full article